English

Oxford Immunotec Global PLC

EDGAR

OXFD Quarterly report (10-Q) · filed 2020-11-03

31 filing records in this dataset, filed from 2013-10-15 to 2020-11-03. Reported financial figures are available; chart coverage varies by period.

Inspect reported changes Compare with another company Historical disclosures Search filings Segments

Watchlist

Latest quarter

Revenue

25 million iso4217-usd

2017 Q4 · iso4217-usd

Exact inputs and evidence

Revenue: 103080000 iso4217-usd Source
Revenue: 78054000 iso4217-usd Source

Operating margin

-56.25%

2017 Q4 · %

Exact inputs and evidence

Operating Income: -53928000 iso4217-usd Source
Operating Income: -39851000 iso4217-usd Source
Revenue: 103080000 iso4217-usd Source
Revenue: 78054000 iso4217-usd Source

Operating cash flow

17.9 million iso4217-usd

2017 Q4 · iso4217-usd

Exact inputs and evidence

Operating Cash Flow: -13122000 iso4217-usd Source
Operating Cash Flow: -31054000 iso4217-usd Source

Free cash flow

17.4 million iso4217-usd

2017 Q4 · iso4217-usd

Exact inputs and evidence

Operating Cash Flow: -13122000 iso4217-usd Source
Operating Cash Flow: -31054000 iso4217-usd Source
Capital Expenditure: 1295000 iso4217-usd Source
Capital Expenditure: 735000 iso4217-usd Source

Cash and cash equivalents: 161 million USD 2020-09-30 Source
Exact value

160621000 USD
Long-term debt including current maturities: 30 million iso4217-usd 2018-06-30 Source
Exact value

30000000 iso4217-usd
Shares outstanding: 26 million shares 2020-09-30 Source
Exact value

25961817 shares

Includes later revisions to earlier periods. Annual charts exclude incomplete years.

Latest filing recorded: 2020-11-03.

Financial data available through: 2019-12-31.

Coverage by financial measure

Revenue: 5 of 11 periods available· newest 2017-12-31
Operating income: 7 of 11 periods available· newest 2019-12-31
Net income: 7 of 11 periods available· newest 2019-12-31
Operating cash flow: 7 of 11 periods available· newest 2019-12-31
Capital expenditure: 7 of 11 periods available· newest 2019-12-31
Total assets: Multiple units; comparison withheld· newest 2019-12-31
Total liabilities: Multiple units; comparison withheld· newest 2019-12-31
Current assets: Multiple units; comparison withheld· newest 2019-12-31
Current liabilities: Multiple units; comparison withheld· newest 2019-12-31
Cash and cash equivalents: Multiple units; comparison withheld· newest 2019-12-31
long term debt: No compatible figures in this window
Shares outstanding: Multiple units; comparison withheld· newest 2019-12-31

Coverage describes values retained in this snapshot. Missing values are not zero; loading limits are reported separately.

What changed year over year

Latest complete year compared with the corresponding period one year earlier. These are measured changes; they do not establish their business causes.

Net income
-101.5%

Prior period

iso4217-usd 120.78 million

2018-01-01 – 2018-12-31
Current period

−iso4217-usd 1.81 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-1809000 − 120779000 = -122588000 iso4217-usd

120779000 iso4217-usd · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-1809000 iso4217-usd · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Net income · Oxford Immunotec Global PLC · 2019-12-31 Oxford Immunotec Global PLC (edgar:1586049) Year-over-year change in Net income: -122588000 iso4217-usd Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:NetIncome: -1809000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#957795 Filing: 000143774920004480 Input fundies:NetIncome: 120779000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#956924 Filing: 000143774920004480
The citation records this snapshot. The page link may show a newer release later.
Operating cash flow
+iso4217-usd 24.96 million

Prior period

−iso4217-usd 32.12 million

2018-01-01 – 2018-12-31
Current period

−iso4217-usd 7.16 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

-7163000 − -32119000 = 24956000 iso4217-usd

-32119000 iso4217-usd · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
-7163000 iso4217-usd · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Operating cash flow · Oxford Immunotec Global PLC · 2019-12-31 Oxford Immunotec Global PLC (edgar:1586049) Year-over-year change in Operating cash flow: 24956000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:OperatingCashFlow: -7163000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#955710 Filing: 000143774920004480 Input fundies:OperatingCashFlow: -32119000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#955954 Filing: 000143774920004480
The citation records this snapshot. The page link may show a newer release later.
Capital expenditure
-69%

Prior period

iso4217-usd 5.35 million

2018-01-01 – 2018-12-31
Current period

iso4217-usd 1.66 million

2019-01-01 – 2019-12-31

Exact inputs and evidence

1658000 − 5350000 = -3692000 iso4217-usd

5350000 iso4217-usd · 2018-01-01 – 2018-12-31
Inspect prior input Prior source
1658000 iso4217-usd · 2019-01-01 – 2019-12-31
Inspect current input Current source

Share or cite

Citation for Year-over-year change in Capital expenditure · Oxford Immunotec Global PLC · 2019-12-31 Oxford Immunotec Global PLC (edgar:1586049) Year-over-year change in Capital expenditure: -3692000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#period-changes-title Computed: Current period minus corresponding prior-year period Input fundies:CapitalExpenditure: 1658000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#1000441 Filing: 000143774920004480 Input fundies:CapitalExpenditure: 5350000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#1000644 Filing: 000143774920004480
The citation records this snapshot. The page link may show a newer release later.

Comparable inputs unavailable for: Revenue.

Where revenue goes

How a period’s revenue divides into costs and what remains as profit. Items marked Derived are calculated by subtraction from reported figures.

2017 2017-01-01 – 2017-12-31

Revenue iso4217-usd 103.08 million 100% of revenue
Cost of revenue iso4217-usd 18.47 million 18% of revenue
Operating expenses iso4217-usd 90.19 million 87% of revenue
Other operating costs Derived iso4217-usd 48.35 million 47% of revenue
Operating income −iso4217-usd 53.93 million −52% of revenue
Tax, interest and other Derived −iso4217-usd 21.04 million −20% of revenue
Net income −iso4217-usd 32.89 million −32% of revenue

Cash

Operating cash flow −iso4217-usd 13.12 million −13% of revenue
Capital expenditure iso4217-usd 1.3 million 1.3% of revenue
Free cash flow Derived −iso4217-usd 14.42 million −14% of revenue

Share of revenue by period

Net income
Tax, interest and other
Operating costs

2013 Operating loss: operating costs were 119% of revenue.
2014 Operating loss: operating costs were 144% of revenue.
2015 Operating loss: operating costs were 139% of revenue.
2016 Operating loss: operating costs were 129% of revenue.
2017 Operating loss: operating costs were 152% of revenue.

Values and sources

Revenue breakdown by annual reporting period
Period	Revenue	Operating costs	Operating income	Tax, interest and other	Net income	Free cash flow	Source
2013 2013-01-01 – 2013-12-31	38784000	46135000 Derived	-7351000	1313000 Derived	-8664000	-7428000 Derived	Source 2013-01-01 – 2013-12-31: 38784000 iso4217-usd Inspect Revenue Open source 2013-01-01 – 2013-12-31: -7351000 iso4217-usd Inspect Operating Income Open source 2013-01-01 – 2013-12-31: -8664000 iso4217-usd Inspect Net Income Open source 2013-01-01 – 2013-12-31: -5619000 iso4217-usd Inspect Operating Cash Flow Open source 2013-01-01 – 2013-12-31: 1809000 iso4217-usd Inspect Capital Expenditure Open source
2014 2014-01-01 – 2014-12-31	49505000	71366000 Derived	-21861000	313000 Derived	-22174000	-23791000 Derived	Source 2014-01-01 – 2014-12-31: 49505000 iso4217-usd Inspect Revenue Open source 2014-01-01 – 2014-12-31: -21861000 iso4217-usd Inspect Operating Income Open source 2014-01-01 – 2014-12-31: -22174000 iso4217-usd Inspect Net Income Open source 2014-01-01 – 2014-12-31: -20777000 iso4217-usd Inspect Operating Cash Flow Open source 2014-01-01 – 2014-12-31: 3014000 iso4217-usd Inspect Capital Expenditure Open source
2015 2015-01-01 – 2015-12-31	62782000	86958000 Derived	-24176000	302000 Derived	-24478000	-19974000 Derived	Source 2015-01-01 – 2015-12-31: 62782000 iso4217-usd Inspect Revenue Open source 2015-01-01 – 2015-12-31: -24176000 iso4217-usd Inspect Operating Income Open source 2015-01-01 – 2015-12-31: -24478000 iso4217-usd Inspect Net Income Open source 2015-01-01 – 2015-12-31: -16549000 iso4217-usd Inspect Operating Cash Flow Open source 2015-01-01 – 2015-12-31: 3425000 iso4217-usd Inspect Capital Expenditure Open source
2016 2016-01-01 – 2016-12-31	86078000	111284000 Derived	-25206000	-2857000 Derived	-22349000	-28167000 Derived	Source 2016-01-01 – 2016-12-31: 86078000 iso4217-usd Inspect Revenue Open source 2016-01-01 – 2016-12-31: -25206000 iso4217-usd Inspect Operating Income Open source 2016-01-01 – 2016-12-31: -22349000 iso4217-usd Inspect Net Income Open source 2016-01-01 – 2016-12-31: -27311000 iso4217-usd Inspect Operating Cash Flow Open source 2016-01-01 – 2016-12-31: 856000 iso4217-usd Inspect Capital Expenditure Open source
2017 2017-01-01 – 2017-12-31	103080000	157008000 Derived	-53928000	-21043000 Derived	-32885000	-14417000 Derived	Source 2017-01-01 – 2017-12-31: 103080000 iso4217-usd Inspect Revenue Open source 2017-01-01 – 2017-12-31: -53928000 iso4217-usd Inspect Operating Income Open source 2017-01-01 – 2017-12-31: -32885000 iso4217-usd Inspect Net Income Open source 2017-01-01 – 2017-12-31: -13122000 iso4217-usd Inspect Operating Cash Flow Open source 2017-01-01 – 2017-12-31: 1295000 iso4217-usd Inspect Capital Expenditure Open source

Amounts are exact, in iso4217-usd.

Growth

Sales over time and how quickly they are changing.

Revenue

Revenue reported for each complete financial period.

iso4217-usd 103.1M 2017

Values and sources

Revenue values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20132013-12-31	Revenue	38784000	Revenue: 38784000 Open source
20142014-12-31	Revenue	49505000	Revenue: 49505000 Open source
20152015-12-31	Revenue	62782000	Revenue: 62782000 Open source
20162016-12-31	Revenue	86078000	Revenue: 86078000 Open source
20172017-12-31	Revenue	103080000	Revenue: 103080000 Open source

Revenue growth

Change in revenue from the same financial period one year earlier.

19.8% 2017

Values and sources

Revenue growth values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Year over year	No prior comparable period	Revenue: 38784000 Open source
20142014-12-31	Year over year	27.6%	Revenue: 49505000 Open source Revenue: 38784000 Open source
20152015-12-31	Year over year	26.8%	Revenue: 62782000 Open source Revenue: 49505000 Open source
20162016-12-31	Year over year	37.1%	Revenue: 86078000 Open source Revenue: 62782000 Open source
20172017-12-31	Year over year	19.8%	Revenue: 103080000 Open source Revenue: 86078000 Open source

Profit and cash

How much revenue becomes profit, and how much cash operations generate.

Profit margins

Operating income, net income and free cash flow as a share of revenue.

Operating margin -52.3% 2017

Net margin -31.9% 2017

Free cash flow margin -14% 2017

Operating margin
Net margin
Free cash flow margin

Values and sources

Profit margins values and source evidence
Period	Series	Value	Source evidence
20132013-12-31	Operating margin	-19%	Operating Income: -7351000 Open source Revenue: 38784000 Open source
20142014-12-31	Operating margin	-44.2%	Operating Income: -21861000 Open source Revenue: 49505000 Open source
20152015-12-31	Operating margin	-38.5%	Operating Income: -24176000 Open source Revenue: 62782000 Open source
20162016-12-31	Operating margin	-29.3%	Operating Income: -25206000 Open source Revenue: 86078000 Open source
20172017-12-31	Operating margin	-52.3%	Operating Income: -53928000 Open source Revenue: 103080000 Open source
20132013-12-31	Net margin	-22.3%	Net Income: -8664000 Open source Revenue: 38784000 Open source
20142014-12-31	Net margin	-44.8%	Net Income: -22174000 Open source Revenue: 49505000 Open source
20152015-12-31	Net margin	-39%	Net Income: -24478000 Open source Revenue: 62782000 Open source
20162016-12-31	Net margin	-26%	Net Income: -22349000 Open source Revenue: 86078000 Open source
20172017-12-31	Net margin	-31.9%	Net Income: -32885000 Open source Revenue: 103080000 Open source
20132013-12-31	Free cash flow margin	-19.2%	Revenue: 38784000 Open source Operating Cash Flow: -5619000 Open source Capital Expenditure: 1809000 Open source
20142014-12-31	Free cash flow margin	-48.1%	Revenue: 49505000 Open source Operating Cash Flow: -20777000 Open source Capital Expenditure: 3014000 Open source
20152015-12-31	Free cash flow margin	-31.8%	Revenue: 62782000 Open source Operating Cash Flow: -16549000 Open source Capital Expenditure: 3425000 Open source
20162016-12-31	Free cash flow margin	-32.7%	Revenue: 86078000 Open source Operating Cash Flow: -27311000 Open source Capital Expenditure: 856000 Open source
20172017-12-31	Free cash flow margin	-14%	Revenue: 103080000 Open source Operating Cash Flow: -13122000 Open source Capital Expenditure: 1295000 Open source

Operating cash flow

Cash generated by the company’s normal business operations.

iso4217-usd -13.1M 2017

Values and sources

Operating cash flow values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20132013-12-31	Operating cash flow	-5619000	Operating Cash Flow: -5619000 Open source
20142014-12-31	Operating cash flow	-20777000	Operating Cash Flow: -20777000 Open source
20152015-12-31	Operating cash flow	-16549000	Operating Cash Flow: -16549000 Open source
20162016-12-31	Operating cash flow	-27311000	Operating Cash Flow: -27311000 Open source
20172017-12-31	Operating cash flow	-13122000	Operating Cash Flow: -13122000 Open source

Free cash flow

Operating cash flow minus capital expenditure for the same period and unit.

iso4217-usd -14.4M 2017

Values and sources

Free cash flow values and source evidence
Period	Series	Value(iso4217-usd)	Source evidence
20132013-12-31	Free cash flow	-7428000	Operating Cash Flow: -5619000 Open source Capital Expenditure: 1809000 Open source
20142014-12-31	Free cash flow	-23791000	Operating Cash Flow: -20777000 Open source Capital Expenditure: 3014000 Open source
20152015-12-31	Free cash flow	-19974000	Operating Cash Flow: -16549000 Open source Capital Expenditure: 3425000 Open source
20162016-12-31	Free cash flow	-28167000	Operating Cash Flow: -27311000 Open source Capital Expenditure: 856000 Open source
20172017-12-31	Free cash flow	-14417000	Operating Cash Flow: -13122000 Open source Capital Expenditure: 1295000 Open source

Balance sheet

Liabilities and short-term ability to meet obligations at each period end.

Liabilities to assets

Total liabilities as a share of total assets.

Not enough comparable data to show this history.

Values and sources

Liabilities to assets values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Liabilities / assets	Not reported	No source recorded
2014-12-31	Liabilities / assets	Not reported	No source recorded
2015-12-31	Liabilities / assets	Not reported	No source recorded
2016-12-31	Liabilities / assets	Not reported	No source recorded
2017-12-31	Liabilities / assets	Not reported	No source recorded

Current assets to current liabilities

Current assets divided by current liabilities.

Not enough comparable data to show this history.

Values and sources

Current assets to current liabilities values and source evidence
Period	Series	Value	Source evidence
2013-12-31	Current assets / current liabilities	Not reported	No source recorded
2014-12-31	Current assets / current liabilities	Not reported	No source recorded
2015-12-31	Current assets / current liabilities	Not reported	No source recorded
2016-12-31	Current assets / current liabilities	Not reported	No source recorded
2017-12-31	Current assets / current liabilities	Not reported	No source recorded

Cash generation

Compare reported profit with operating cash and capital spending. Free cash flow is calculated as operating cash flow minus capital expenditure when both exact, consolidated amounts match the same period and unit.

Cash generation by annual reporting period
Period	Net income	Operating cash flow	Capital expenditure	Free cash flow
2013 2013-01-01 – 2013-12-31	−iso4217-usd 8.66 million Exact value Exact value: -8664000 iso4217-usd 2013-01-01 – 2013-12-31: -8664000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Oxford Immunotec Global PLC · 2013-12-31 Oxford Immunotec Global PLC (edgar:1586049) Net Income: -8664000 iso4217-usd Concept: fundies:NetIncome Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ANetIncome&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: -8664000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774916026453/oxfd-20151231.xml#869852 Filing: 000143774916026453 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 5.62 million Exact value Exact value: -5619000 iso4217-usd 2013-01-01 – 2013-12-31: -5619000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oxford Immunotec Global PLC · 2013-12-31 Oxford Immunotec Global PLC (edgar:1586049) Operating Cash Flow: -5619000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3AOperatingCashFlow&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -5619000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774916026453/oxfd-20151231.xml#869357 Filing: 000143774916026453 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 1.81 million Exact value Exact value: 1809000 iso4217-usd 2013-01-01 – 2013-12-31: 1809000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oxford Immunotec Global PLC · 2013-12-31 Oxford Immunotec Global PLC (edgar:1586049) Capital Expenditure: 1809000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ACapitalExpenditure&period=2013-12-31&surface=latest&period_type=duration&start=2013-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 1809000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774916026453/oxfd-20151231.xml#906471 Filing: 000143774916026453 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 7.43 million Calculation and evidence -5619000 − 1809000 iso4217-usd Exact free cash flow: -7428000 iso4217-usd 2013-01-01 – 2013-12-31: -5619000 iso4217-usd · Inspect Operating Cash Flow · Source 2013-01-01 – 2013-12-31: 1809000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oxford Immunotec Global PLC · 2013-12-31 Oxford Immunotec Global PLC (edgar:1586049) Free cash flow: -7428000 iso4217-usd Concept: free-cash-flow Period: 2013-01-01 to 2013-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -5619000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774916026453/oxfd-20151231.xml#869357 Filing: 000143774916026453 Input fundies:CapitalExpenditure: 1809000 iso4217-usd (2013-01-01 to 2013-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774916026453/oxfd-20151231.xml#906471 Filing: 000143774916026453 The citation records this snapshot. The page link may show a newer release later.
2014 2014-01-01 – 2014-12-31	−iso4217-usd 22.17 million Exact value Exact value: -22174000 iso4217-usd 2014-01-01 – 2014-12-31: -22174000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Oxford Immunotec Global PLC · 2014-12-31 Oxford Immunotec Global PLC (edgar:1586049) Net Income: -22174000 iso4217-usd Concept: fundies:NetIncome Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ANetIncome&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: -22174000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774917003451/oxfd-20161231.xml#1273747 Filing: 000143774917003451 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 20.78 million Exact value Exact value: -20777000 iso4217-usd 2014-01-01 – 2014-12-31: -20777000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oxford Immunotec Global PLC · 2014-12-31 Oxford Immunotec Global PLC (edgar:1586049) Operating Cash Flow: -20777000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3AOperatingCashFlow&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -20777000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774917003451/oxfd-20161231.xml#1272817 Filing: 000143774917003451 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 3.01 million Exact value Exact value: 3014000 iso4217-usd 2014-01-01 – 2014-12-31: 3014000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oxford Immunotec Global PLC · 2014-12-31 Oxford Immunotec Global PLC (edgar:1586049) Capital Expenditure: 3014000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ACapitalExpenditure&period=2014-12-31&surface=latest&period_type=duration&start=2014-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 3014000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774917003451/oxfd-20161231.xml#1337823 Filing: 000143774917003451 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 23.79 million Calculation and evidence -20777000 − 3014000 iso4217-usd Exact free cash flow: -23791000 iso4217-usd 2014-01-01 – 2014-12-31: -20777000 iso4217-usd · Inspect Operating Cash Flow · Source 2014-01-01 – 2014-12-31: 3014000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oxford Immunotec Global PLC · 2014-12-31 Oxford Immunotec Global PLC (edgar:1586049) Free cash flow: -23791000 iso4217-usd Concept: free-cash-flow Period: 2014-01-01 to 2014-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -20777000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774917003451/oxfd-20161231.xml#1272817 Filing: 000143774917003451 Input fundies:CapitalExpenditure: 3014000 iso4217-usd (2014-01-01 to 2014-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774917003451/oxfd-20161231.xml#1337823 Filing: 000143774917003451 The citation records this snapshot. The page link may show a newer release later.
2015 2015-01-01 – 2015-12-31	−iso4217-usd 24.48 million Exact value Exact value: -24478000 iso4217-usd 2015-01-01 – 2015-12-31: -24478000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Oxford Immunotec Global PLC · 2015-12-31 Oxford Immunotec Global PLC (edgar:1586049) Net Income: -24478000 iso4217-usd Concept: fundies:NetIncome Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ANetIncome&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: -24478000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774918003397/oxfd-20171231.xml#1222328 Filing: 000143774918003397 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 16.55 million Exact value Exact value: -16549000 iso4217-usd 2015-01-01 – 2015-12-31: -16549000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oxford Immunotec Global PLC · 2015-12-31 Oxford Immunotec Global PLC (edgar:1586049) Operating Cash Flow: -16549000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3AOperatingCashFlow&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -16549000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774918003397/oxfd-20171231.xml#1221398 Filing: 000143774918003397 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 3.43 million Exact value Exact value: 3425000 iso4217-usd 2015-01-01 – 2015-12-31: 3425000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oxford Immunotec Global PLC · 2015-12-31 Oxford Immunotec Global PLC (edgar:1586049) Capital Expenditure: 3425000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ACapitalExpenditure&period=2015-12-31&surface=latest&period_type=duration&start=2015-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 3425000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774918003397/oxfd-20171231.xml#1286333 Filing: 000143774918003397 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 19.97 million Calculation and evidence -16549000 − 3425000 iso4217-usd Exact free cash flow: -19974000 iso4217-usd 2015-01-01 – 2015-12-31: -16549000 iso4217-usd · Inspect Operating Cash Flow · Source 2015-01-01 – 2015-12-31: 3425000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oxford Immunotec Global PLC · 2015-12-31 Oxford Immunotec Global PLC (edgar:1586049) Free cash flow: -19974000 iso4217-usd Concept: free-cash-flow Period: 2015-01-01 to 2015-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -16549000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774918003397/oxfd-20171231.xml#1221398 Filing: 000143774918003397 Input fundies:CapitalExpenditure: 3425000 iso4217-usd (2015-01-01 to 2015-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774918003397/oxfd-20171231.xml#1286333 Filing: 000143774918003397 The citation records this snapshot. The page link may show a newer release later.
2016 2016-01-01 – 2016-12-31	−iso4217-usd 22.35 million Exact value Exact value: -22349000 iso4217-usd 2016-01-01 – 2016-12-31: -22349000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Oxford Immunotec Global PLC · 2016-12-31 Oxford Immunotec Global PLC (edgar:1586049) Net Income: -22349000 iso4217-usd Concept: fundies:NetIncome Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ANetIncome&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: -22349000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1094916 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 27.31 million Exact value Exact value: -27311000 iso4217-usd 2016-01-01 – 2016-12-31: -27311000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oxford Immunotec Global PLC · 2016-12-31 Oxford Immunotec Global PLC (edgar:1586049) Operating Cash Flow: -27311000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3AOperatingCashFlow&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -27311000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1093946 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 856,000 Exact value Exact value: 856000 iso4217-usd 2016-01-01 – 2016-12-31: 856000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oxford Immunotec Global PLC · 2016-12-31 Oxford Immunotec Global PLC (edgar:1586049) Capital Expenditure: 856000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ACapitalExpenditure&period=2016-12-31&surface=latest&period_type=duration&start=2016-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 856000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1152963 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 28.17 million Calculation and evidence -27311000 − 856000 iso4217-usd Exact free cash flow: -28167000 iso4217-usd 2016-01-01 – 2016-12-31: -27311000 iso4217-usd · Inspect Operating Cash Flow · Source 2016-01-01 – 2016-12-31: 856000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oxford Immunotec Global PLC · 2016-12-31 Oxford Immunotec Global PLC (edgar:1586049) Free cash flow: -28167000 iso4217-usd Concept: free-cash-flow Period: 2016-01-01 to 2016-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -27311000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1093946 Filing: 000143774919005832 Input fundies:CapitalExpenditure: 856000 iso4217-usd (2016-01-01 to 2016-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1152963 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.
2017 2017-01-01 – 2017-12-31	−iso4217-usd 32.89 million Exact value Exact value: -32885000 iso4217-usd 2017-01-01 – 2017-12-31: -32885000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Oxford Immunotec Global PLC · 2017-12-31 Oxford Immunotec Global PLC (edgar:1586049) Net Income: -32885000 iso4217-usd Concept: fundies:NetIncome Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ANetIncome&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: -32885000 iso4217-usd (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1095788 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 13.12 million Exact value Exact value: -13122000 iso4217-usd 2017-01-01 – 2017-12-31: -13122000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oxford Immunotec Global PLC · 2017-12-31 Oxford Immunotec Global PLC (edgar:1586049) Operating Cash Flow: -13122000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3AOperatingCashFlow&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -13122000 iso4217-usd (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1093701 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 1.3 million Exact value Exact value: 1295000 iso4217-usd 2017-01-01 – 2017-12-31: 1295000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oxford Immunotec Global PLC · 2017-12-31 Oxford Immunotec Global PLC (edgar:1586049) Capital Expenditure: 1295000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ACapitalExpenditure&period=2017-12-31&surface=latest&period_type=duration&start=2017-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 1295000 iso4217-usd (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1152760 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 14.42 million Calculation and evidence -13122000 − 1295000 iso4217-usd Exact free cash flow: -14417000 iso4217-usd 2017-01-01 – 2017-12-31: -13122000 iso4217-usd · Inspect Operating Cash Flow · Source 2017-01-01 – 2017-12-31: 1295000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oxford Immunotec Global PLC · 2017-12-31 Oxford Immunotec Global PLC (edgar:1586049) Free cash flow: -14417000 iso4217-usd Concept: free-cash-flow Period: 2017-01-01 to 2017-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -13122000 iso4217-usd (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1093701 Filing: 000143774919005832 Input fundies:CapitalExpenditure: 1295000 iso4217-usd (2017-01-01 to 2017-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774919005832/oxfd-20181231.xml#1152760 Filing: 000143774919005832 The citation records this snapshot. The page link may show a newer release later.
2018 2018-01-01 – 2018-12-31	iso4217-usd 120.78 million Exact value Exact value: 120779000 iso4217-usd 2018-01-01 – 2018-12-31: 120779000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Oxford Immunotec Global PLC · 2018-12-31 Oxford Immunotec Global PLC (edgar:1586049) Net Income: 120779000 iso4217-usd Concept: fundies:NetIncome Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ANetIncome&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: 120779000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#956924 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 32.12 million Exact value Exact value: -32119000 iso4217-usd 2018-01-01 – 2018-12-31: -32119000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oxford Immunotec Global PLC · 2018-12-31 Oxford Immunotec Global PLC (edgar:1586049) Operating Cash Flow: -32119000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3AOperatingCashFlow&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -32119000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#955954 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 5.35 million Exact value Exact value: 5350000 iso4217-usd 2018-01-01 – 2018-12-31: 5350000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oxford Immunotec Global PLC · 2018-12-31 Oxford Immunotec Global PLC (edgar:1586049) Capital Expenditure: 5350000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ACapitalExpenditure&period=2018-12-31&surface=latest&period_type=duration&start=2018-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 5350000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#1000644 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 37.47 million Calculation and evidence -32119000 − 5350000 iso4217-usd Exact free cash flow: -37469000 iso4217-usd 2018-01-01 – 2018-12-31: -32119000 iso4217-usd · Inspect Operating Cash Flow · Source 2018-01-01 – 2018-12-31: 5350000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oxford Immunotec Global PLC · 2018-12-31 Oxford Immunotec Global PLC (edgar:1586049) Free cash flow: -37469000 iso4217-usd Concept: free-cash-flow Period: 2018-01-01 to 2018-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -32119000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#955954 Filing: 000143774920004480 Input fundies:CapitalExpenditure: 5350000 iso4217-usd (2018-01-01 to 2018-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#1000644 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.
2019 2019-01-01 – 2019-12-31	−iso4217-usd 1.81 million Exact value Exact value: -1809000 iso4217-usd 2019-01-01 – 2019-12-31: -1809000 iso4217-usd Inspect Net Income Open source Share or cite Citation for Net Income · Oxford Immunotec Global PLC · 2019-12-31 Oxford Immunotec Global PLC (edgar:1586049) Net Income: -1809000 iso4217-usd Concept: fundies:NetIncome Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ANetIncome&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=iso4217-usd&dimensions= Input fundies:NetIncome: -1809000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#957795 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 7.16 million Exact value Exact value: -7163000 iso4217-usd 2019-01-01 – 2019-12-31: -7163000 iso4217-usd Inspect Operating Cash Flow Open source Share or cite Citation for Operating Cash Flow · Oxford Immunotec Global PLC · 2019-12-31 Oxford Immunotec Global PLC (edgar:1586049) Operating Cash Flow: -7163000 iso4217-usd Concept: fundies:OperatingCashFlow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3AOperatingCashFlow&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=iso4217-usd&dimensions= Input fundies:OperatingCashFlow: -7163000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#955710 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.	iso4217-usd 1.66 million Exact value Exact value: 1658000 iso4217-usd 2019-01-01 – 2019-12-31: 1658000 iso4217-usd Inspect Capital Expenditure Open source Share or cite Citation for Capital Expenditure · Oxford Immunotec Global PLC · 2019-12-31 Oxford Immunotec Global PLC (edgar:1586049) Capital Expenditure: 1658000 iso4217-usd Concept: fundies:CapitalExpenditure Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049/explain?concept=fundies%3ACapitalExpenditure&period=2019-12-31&surface=latest&period_type=duration&start=2019-01-01&unit=iso4217-usd&dimensions= Input fundies:CapitalExpenditure: 1658000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#1000441 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.	−iso4217-usd 8.82 million Calculation and evidence -7163000 − 1658000 iso4217-usd Exact free cash flow: -8821000 iso4217-usd 2019-01-01 – 2019-12-31: -7163000 iso4217-usd · Inspect Operating Cash Flow · Source 2019-01-01 – 2019-12-31: 1658000 iso4217-usd · Inspect Capital Expenditure · Source Share or cite Citation for Free cash flow · Oxford Immunotec Global PLC · 2019-12-31 Oxford Immunotec Global PLC (edgar:1586049) Free cash flow: -8821000 iso4217-usd Concept: free-cash-flow Period: 2019-01-01 to 2019-12-31 Values: Latest reported Published: 2026-11-02T18:04:48Z Snapshot: fee39ab9da2ec6e0d64b11ac4212a48b5c028adf2a50ce0efb49b877ab2b1e6a Dimensions: Consolidated View: https://fundies.io/companies/edgar/1586049?view=overview&cadence=annual&surface=latest#cash-generation-title Computed: Operating cash flow minus capital expenditure Input fundies:OperatingCashFlow: -7163000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#955710 Filing: 000143774920004480 Input fundies:CapitalExpenditure: 1658000 iso4217-usd (2019-01-01 to 2019-12-31) Dimensions: Consolidated Source: https://www.sec.gov/Archives/edgar/data/1586049/000143774920004480/oxfd-20191231.xml#1000441 Filing: 000143774920004480 The citation records this snapshot. The page link may show a newer release later.

Capital expenditure uses the canonical mapped positive-spending convention. A missing, ambiguous, incompatible, or negative-sign input is left blank. Values use the latest reported version.

Dataset coverage and company identifiers

Coverage reflects filings processed into this Fundies dataset; it does not imply every source filing is loaded.

31 filings · 2,564 latest values · 2,564 originally reported values

Dataset published 2026-11-02. Source filing dates and reporting periods are shown separately.

Identifiers: 0001586049, 1586049, OXFD, edgar:1586049, oxfd

Also known as Oxford Immunotec Global PLC

Oxford Immunotec Global PLC

Latest quarter

Revenue

Operating margin

Operating cash flow

Free cash flow

Company performance

What changed year over year

Net income

Operating cash flow

Capital expenditure

Where revenue goes

2017 2017-01-01 – 2017-12-31

Cash

Share of revenue by period

Growth

Profit and cash

Balance sheet

Cash generation